Drug discovery approaches targeting the PI3K/Akt pathway in cancer

Oncogene

Volumn 27, Issue 41, 2008, Pages 5511-5526

  Garcia Echeverria, C ^a   Sellers, W R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Akt; Cancer therapy; Drug design; HSP90; PDK1; Phosphoinositide 3 kinase

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 7 HYDROXYSTAUROSPORINE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTINEOPLASTIC AGENT; BX 320; BX 517; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GDC 0941; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; MIDOSTAURIN; OSU 03013; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK 75; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PWT 458; PX 866; RUBOXISTAURIN; SF 1126; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765;

BREAST CANCER; CANCER THERAPY; CATALYSIS; COLON CARCINOMA; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GLIOMA; HUMAN; INSULIN RESISTANCE; KIDNEY CARCINOMA; LACTIC ACIDOSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE; VOMITING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPID METABOLISM; MODELS, BIOLOGICAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 51849098272     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.246     Document Type: Review

References (120)

1. Abraham RT. (2004). PI3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair 3: 883-887.
2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al. (1996). Mechanism of activation of protein kinase B by insulin and IGF-I. EMBO J 15: 6541-6551.
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr Biol 7: 261-269.
4. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P et al. (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621.
5. Barnett SF, Defeo-Jones D, Fu S, Hancok PJ, Haskell K, Jones RE et al. (2005). Identification and characterization of pleckstrin-homology- domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408.
6. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. (2002). Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866.
7. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D et al. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17: 313-325.
8. Biondi RM, Cheung PCF, Casamayor A, Deak M, Currie RA, Alessi DR. (2000). Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 19: 979-988.
9. Bishop SC, Burlison JA, Blagg BSJ. (2007). Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Med Chem 7: 369-388.
10. Bozulic L, Surucu B, Hynx D, Hemmings BA. (2008). PKBa/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30: 203-213.
11. Breitenlechner CB, Friebe WG, Brunet E, Werner G, Graul K, Thomas U et al. (2005). Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J Med Chem 48: 163-170.
12. Breitenlechner CB, Wegge T, Berillon L, Graul K, Marzenell K, Friebe WG et al. (2004). Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 47: 1375-1390.
13. Brian PW, Hemming HG, Norris GLF. (1957). Wotmannin, an antibiotic produced by penicillium wortmanni. Br Mycol Soc Trans 40: 365-368.
14. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE et al. (2008). 4,5-Diaryl-lisoxazole hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218.
15. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JFM. (2008). The PTEN/PI3K/Akt signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198.
16. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the plecstrin homology domain of Akt1 in cancer. Nature 448: 439-444.
17. Casamayor A, Morrice NA, Alessi DR. (1999). Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342: 287-292.
18. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240-248.
19. Chen JS, Zhou LJ, Entin-Meer M, Yang X, Donker M, Knight ZA et al. (2008). Characterization of structurally distinct, isoform-selective phosphoinosite 30-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 7: 841-850.
20. Chiosis G, Vilenchik M, Kim J, Solit D. (2004). Hsp90: the vulnerable chaperone. Drug Discov Today 9: 881-888.
21. Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. (2004). In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clinl Cancer Res 10: 5242-5252.
22. Davies SP, Reddy H, Caivano M, Cohen P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
23. Davies TD, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CCF, McHardy T et al. (2007). A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol 367: 882-894.
24. Davis PD, Elliott LH, Harris W, Hill CH, Hurst SA, Keech E et al. (1992). Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem 35: 994-1001.
25. Downward J. (2006). PI-3kinase, Akt and cell survival. Semin Cell Dev Biol 15: 177-182.
26. Dymock BW, Drysdale MJ, McDonald E, Workman P. (2004). Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin Ther Pat 14: 837-847.
27. Eccles S, Massey A, Raynaud FI, Sharp SY, Bax G, Valenti M et al. (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
28. Engel J, Hilgard P, Klenner T, Kutscher B, Nossner G, Traiser M et al. (2000). Perifosine: oncolytic, ether phospholipid. Drugs Future 25: 1257-1260.
29. Engelman JA, Chen L, McNamara K, Upadhyay R, Crosby K, Maira M et al. (2008). Differential efficacy of PI3K inhibition in PIK3CA and K-Ras driven murine lung cancers (submitted).
30. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T et al. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23: 569-575.
31. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM et al. (2007). A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67: 7960-7965.
32. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D et al. (2005). Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280: 19867-19874.
33. Feng J, Park J, Cron P, Hess D, Hemmings BA. (2004). Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279: 41189-41196.
34. Foster PG. (2007). Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. 19th AACR-NCI-EORTC Meeting (abstract C199).
35. Fujita N, Tsuruo T. (2003). Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer Chemother Pharmacol 52: S24-S28.
36. Fujita N, Sato S, Ishida A, Tsuruo T. (2002). Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 277: 10346-10353.
37. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A et al. (2008). A vascular targeted pan phosphoinosite 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68: 206-215.
38. Gassel M, Breitenlechner CB, Ruger P, Jucknischke U, Schneider T, Huber R et al. (2003). Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (Akt). J Mol Biol 329: 1021-1034.
39. Ge J, Normant E, Porter JR, Dembski MS, Gao Y, Georges AT et al. (2008). Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-Amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606-4615.
40. Han E-H, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T et al. (2007). Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26: 5655-5661.
41. Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE et al. (2008). Optimization of 2,3,5-trisubstitued pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. Bioorg Med Chem Lett 18: 2194-2197.
42. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H et al. (2007). Pharmacodynamic markers of perifosine efficacy. Clinc Cancer Res 13: 7421-7431.
43. Hill MM, Hemmings BA. (2002). Inhibition of protein kinase B/Akt implications for cancer therapy. Pharmacol Ther 93: 243-251.
44. Hill MM, Andjelkovic M, Brazil DP, Ferrari S, Fabbro D, Hemmings BA. (2001). Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 276: 25643-25646.
45. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig H-H et al. (2005). In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldnamycin derivative. Cancer Chemother Pharmacol 58: 115-125.
46. Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K et al. (2007). The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 6: 2505-2514.
47. Hsu AL, Chingm TT, Wang DS, Song S, Rangnekar VM, Chen CS. (2000). The cyclooxygenase-2 inhibitor celocoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403.
48. Huang C-H, Mandelker D, Schmidt-Kittler O, Samuels Y, Veculescu VE, Kinzler KW et al. (2007). The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kαmutations. Science 318: 1744-1748.
49. Huston A, Leleu X, Jia X, Moreau A-S, Ngo HT, Runnels J et al. (2008). Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res 14: 865-874.
50. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P et al. (2005). The phosphatidylionositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4: 1349-1357.
51. Islam I, Brown G, Bryant J, Hrvatin P, Kochanny MJ, Phillips GB et al. (2007a). Indoline-based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett 17: 3819-3825.
52. Islam I, Bryant J, Chou Y-L, Kochanny MJ, Lee W, Phillips GB et al. (2007b). Indoline-based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett 17: 3814-3818.
53. Janin YL. (2005). Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J Med Chem 48: 7503-7512.
54. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J et al. (2008). NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10: R33.
55. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P et al. (2003). Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102: 1824-1832.
56. Jones PF, Jakubowicz T, Hemmings BA. (1991a). Molecular cloning of a second form of rac protein kinase. Cell Regul 2: 1001-1009.
57. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. (1991b). Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 88: 4171-4175.
58. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K et al. (2004). Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12: 4749-4759.
59. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. (2006). Pharmacological map of the PI3K family defines a role for p110αin insulin signaling. Cell 125: 733-747.
60. Komander D, Fairservice A, Deak M, Kular GS, Prescott AR, Peter Downes C et al. (2004). Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J 23: 3918-3928.
61. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, van Aalten DMF. (2003). Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375: 255-262.
62. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. (2003). Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2: 1093-1103.
63. Kondapaka SB, Zarnowski MJ, Yver DR, Sausville EA, Cushman SW. (2004). 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylatio n. A basis for decreased insulin-stimulated glucose transport. Clin Cancer Res 10: 7192-7198.
64. Kumar CC, Diao R, Yin Z, Liu Y, Samatar AA, Madison V et al. (2001). Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim Biophys Acta 1526: 257-268.
65. Laird D. (2007). XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. 19th AACR-NCI-EORTC Meeting (abstract B250).
66. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L et al. (2002). Essential role of PDK1 in regulating cell size and development in mice. EMBO J 21: 3728-3738.
67. Li Q, Zhu GD. (2002). Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2: 939-971.
68. Li X, Luwor R, Lu Y, Liang K, Fan Z. (2006). Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25: 525-535.
69. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D et al. (2005). Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15: 761-764.
70. Lundgren K, Zhang H, Kamal A, Lough R, Timple N, Sensintaffar J et al. (2007). BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models. 19th AACR-NCI-EORTC Meeting (abstract B161).
71. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R et al. (2005). Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Res 4: 977-986.
72. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. (2008a). Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTor inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (in press); e-pub ahead of print.
73. Maira S-M, Voliva C, Garcia-Echeverria C. (2008b). Class IA PI3 Kinase: from their biological implication in human cancers to drug discovery. Expert Opin Ther Targets 12: 223-238.
74. Marrer E, Maira S-M, Schnell C, Garcia-Echeverria C. (2008). Integrative approaches to investigate the molecular basis of the in vivo activity of NVP-BEZ235, a dual pan-PI3K/mTOR inhibitor. Proc Am Assoc Cancer Res AACR 99th Annual Meeting (abstract 215).
75. Mitsiades CS, Mitsiades N, Koutsilieris M. (2004). The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4: 235-256.
76. Modi S, Stopeck AT, Gordon MS,Mendelson D, Solit DB, Bagatell R et al. (2007). Combination of trastuzumab and tanespimycin (17-AAG, KOS-593) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: a Phase I dose escalation study. J Clin Oncol 25: 5410-5417.
77. Mora A, Komander D, van Aalten DMF, Alessi DR. (2004). PDK1, the master regulator of AGC kinase signal transduction. Sem Cell Dev Biol 15: 161-170.
78. Neckers L, Neckers K. (2002). Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Exp Opin Emerg Drugs 7: 277-288.
79. Patnaik A, Lorusso PM, Tabernero J, Laird AD, Aggarwal SK, Papadopoulos KP. (2007). Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a phase I clinical trial. EORTC-Meeting (abstract B265).
80. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J et al. (2005). A Phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4: 1133-1137.
81. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingan S, Friedlan D, Agarwala SV et al. (2007). Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13: 1769-1774.
82. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840-5850.
83. Redaelli A, Lee JM, Stephens JM, Pashos CL. (2003). Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 3: 695-710.
84. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ et al. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68: 2366-2374.
85. Roe SM, Podromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. (1999). Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266.
86. Ruiter GA, Zerp SF, Bartelin H, Van Blitterswijk WJ, Verheij M. (2003). Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14: 167-173.
87. Safa O, Parkin SM, Bibby MC. (1998). Morphological changes and cytokine gene expression in tumor xenografts following treatment with alkylphosphocholines hexadecylphosphocholine and perifosine. Drugs Today 34: 15-26.
88. Sarbassov D, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
89. Sato S, Fujita N, Tsuruo T. (2002). Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727-1738.
90. Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng Y, Curtin NJ et al. (2003). Structure-based design of 2-arylamino-4-cyclohexylmethyl-5- nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett 13: 3079-3082.
91. Schnell C, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PMJ, Dartois C et al. (2008). Effects of the dual PI3K/mTOR inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res; e-pub ahead of print.
92. Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits growth of cancer cells with activating PI3K mutations. Cancer Res; e-pub ahead of print.
93. Shapiro GI, Edelman G, Calvo E, Aggarwal SK, Laird AD. (2007). Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor. 19th AACR-NCI-EORTC Meeting (abstract C205).
94. Shi Y, Liu X, Han E, Guan R, Shoemaker AR, Oleksijew A et al. (2005). Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia 7: 992-1000.
95. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. (2003). Inhibition of Heat Shock Protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63: 2139-2144.
96. Stebbins CE, Russo AA, Scheneider C, Rosen N, Hartl FU, Pavletich NP. (1997). Crystal structure of an Hsp90-geldanamycin complex: target a protein chaperone by an antitumour agent. Cell 89: 239-250.
97. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB et al. (1998). Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-714.
98. Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF et al. (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277: 567-570.
99. Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S et al. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia (advance online publication).
100. Sydor J, Normant E, Pien CS, Porter JR, Ge J, Grenier L et al. (2006). Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103: 17408-17413.
101. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW et al. (2004). Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 12: 5317-5329.
102. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morito M, Kakeji Y et al. (2008). Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36.
103. Toral-Barza L, Zhang W-G, Huang X, McDonald LA, Salaski EJ, Barbieri LR et al. (2007). Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of Akt/PKB: mechanistic involvement of Akt catalytic action loop cysteines. Mol Cancer Ther 6: 3028-3038.
104. Traiser M, Reichert S, Voss A. (1998). Current development status of the second generation alkylphosphochloline analog perifosine. Drugs Today 34: 67-71.
105. Vlahos CJ, Matter WF, Hui KY, Brown RF. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
106. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. (2001). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Molecular Cell 6: 909-919.
107. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. (2000). Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402: 313-320.
108. Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S et al. (2007). UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 106: 305-310.
109. Weterings E, Chen DJ. (2007). DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys? J Cell Biol 179: 183-186.
110. Whitesell L, Lindquist SL. (2005). Hsp90 and the chaperoning of cancer. Nat Rev 5: 761-772.
111. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD et al. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16: 1722-1733.
112. Yan Y, Backer JM. (2007). Regulation of class III (Vps34) PI3Ks. Biochem Soc Trans 35: 239-241.
113. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. (2002a). Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9: 940-944.
114. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA et al. (2002b). Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Molecular Cell 9: 1227-1240.
115. Yu K, Lucas J, Zhu T, Zask A, Gaydos C, Toral-Barza L et al. (2005). PWT-458, a novel pegylated-17-dydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4: 538-545.
116. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J et al. (2008). The role of class IA PI3K in vasculogenesis and tumor angiogenesis. Proc Natl Acad Sci USA (advance online publication).
117. Zahler S, Tietze S, Totzke F, Kubbutat M, Meijer L, Vollmar AM et al. (2007). Inverse in silico screening for identification of kinase inhibitor targets. Chem Biol 14: 1207-1214.
118. Zhao Z, Leister WH, Robinson RG, Stanley FB, Defeo-Jones D, Jones RE et al. (2005). Discovery of 2,3,5-trisubstitued pyridine derivatives as potent Akt and Akt2 dual inhibitors. Bioorg Med Chem Lett 15: 905-909.
119. Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD et al. (2008). Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett 18: 49-53.
120. Zhu J, Huang J-W, Tseng P-H, Yang Y-T, Fowble J, Shiau C-W et al. (2004). From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Research 64: 4309-4318.